{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:28:47Z","timestamp":1787020127878,"version":"build-2736575974"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003945","name":"Link\u00f6ping University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003945","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Prim. Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Previous studies have shown inconsistent results for the microvascular complication risk in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD). In addition, many of these studies have been done in specialist care setting. We therefore aimed to explore the association between MASLD and chronic kidney disease, retinopathy, neuropathy, and diabetic foot ulcers in a primary care setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants with type 2 diabetes were recruited in primary care. Hepatic triglyceride content was assessed using magnetic resonance imaging with liver proton density fat fraction (MASLD\u2009\u2265\u20095%) or vibration-controlled transient elastography with controlled attenuation parameter (MASLD\u2009\u2265\u2009248 dB\/m), and hepatic fibrosis was assessed using vibration-controlled transient elastography (advanced fibrosis\u2009\u2265\u200910\u00a0kPa). Data on chronic kidney disease, retinopathy, neuropathy, and diabetic foot ulcers were collected from medical records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 308 participants were included. The median duration of diabetes was 7 years (IQR 3\u201313). MASLD was present in 181 participants (58.8%). Of these, 161 (52.3%) showed no evidence of advanced fibrosis, while 20 (6.5%) were assessed as having advanced fibrosis. Neuropathy was present in 64 participants (20.8%), retinopathy in 60 (19.5%), chronic kidney disease in 59 (19.2%), and diabetic foot ulcers in 13 (4.2%). No significant differences in these complications were observed between participants with and without MASLD. However, participants with MASLD and a higher histopathological fibrosis stage had an increased risk of microvascular complications in our study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Participants with type 2 diabetes and concomitant MASLD recruited in primary care, did not have an increased risk of chronic kidney disease, neuropathy, or retinopathy, supporting previous findings of risk variation across different ethnicities and geographic locations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Clinical trial number NCT03864510 (registration date 2019-02-12).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12875-025-03096-2","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:48:11Z","timestamp":1762843691000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Microvascular complications of type 2 diabetes with or without MASLD: the EPSOMIP study, a primary care cohort study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8524-1900","authenticated-orcid":false,"given":"Martin","family":"Bergram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stergios","family":"Kechagias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Iredahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wile","family":"Balkhed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Dahlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Ekstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"R\u00e5dholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"4","key":"3096_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u201347.","journal-title":"Hepatology"},{"issue":"1","key":"3096_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1103-x","volume":"16","author":"M Alexander","year":"2018","unstructured":"Alexander M, Loomis AK, Fairburn-Beech J, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, et al. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Med. 2018;16(1):130.","journal-title":"BMC Med"},{"issue":"2","key":"3096_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/imj.13667","volume":"48","author":"PJ Patel","year":"2018","unstructured":"Patel PJ, Banh X, Horsfall LU, Hayward KL, Hossain F, Johnson T, et al. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. Intern Med J. 2018;48(2):144\u201351.","journal-title":"Intern Med J"},{"key":"3096_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-016-1946-1","volume":"9","author":"S Polanco-Briceno","year":"2016","unstructured":"Polanco-Briceno S, Glass D, Stuntz M, Caze A. Awareness of nonalcoholic steatohepatitis and associated practice patterns of primary care physicians and specialists. BMC Res Notes. 2016;9:157.","journal-title":"BMC Res Notes"},{"issue":"3","key":"3096_CR5","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/hep.28940","volume":"65","author":"M van Asten","year":"2017","unstructured":"van Asten M, Verhaegh P, Koek G, Verbeek J. The increasing burden of NAFLD fibrosis in the general population: time to bridge the gap between hepatologists and primary care. Hepatology. 2017;65(3):1078.","journal-title":"Hepatology"},{"issue":"1","key":"3096_CR6","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2021.1984572","volume":"57","author":"M Bergram","year":"2021","unstructured":"Bergram M, Nasr P, Iredahl F, Kechagias S, R\u00e5dholm K, Ekstedt M. Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish primary health care. Scand J Gastroenterol. 2021;(1):10. https:\/\/doi.org\/10.1080\/00365521.2021.1984572.","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"3096_CR7","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/hep.25772","volume":"56","author":"R Loomba","year":"2012","unstructured":"Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012;56(3):943\u201351.","journal-title":"Hepatology"},{"key":"3096_CR8","unstructured":"Nationella Diabetesregistret \u00e5rsrapport. 2023: The Swedish National Diabetes Register; 2024. Available from: https:\/\/ndr.registercentrum.se. Accessed 2025-10-15."},{"issue":"4","key":"3096_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1053\/jhep.2003.50161","volume":"37","author":"G Marchesini","year":"2003","unstructured":"Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917\u201323.","journal-title":"Hepatology"},{"issue":"5","key":"3096_CR10","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/jgh.13264","volume":"31","author":"S Ballestri","year":"2016","unstructured":"Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(5):936\u201344.","journal-title":"J Gastroenterol Hepatol"},{"key":"3096_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11040968","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Dalbeni A, Beatrice G, Cappelli D, Gomez-Peralta F. Non-alcoholic fatty liver disease and risk of macro- and microvascular complications in patients with type 2 diabetes. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11040968.","journal-title":"J Clin Med"},{"key":"3096_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108884","volume":"177","author":"I Mikolasevic","year":"2021","unstructured":"Mikolasevic I, Rahelic D, Turk-Wensween T, Ruzic A, Domislovic V, Hauser G, et al. Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: a multicenter study. Diabetes Res Clin Pract. 2021;177:108884.","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"3096_CR13","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/jdi.13489","volume":"12","author":"D Song","year":"2021","unstructured":"Song D, Li C, Wang Z, Zhao Y, Shen B, Zhao W. Association of non-alcoholic fatty liver disease with diabetic retinopathy in type 2 diabetic patients: a meta-analysis of observational studies. J Diabetes Investig. 2021;12(8):1471\u20139.","journal-title":"J Diabetes Investig"},{"issue":"6","key":"3096_CR14","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.pcd.2019.03.009","volume":"13","author":"M Afarideh","year":"2019","unstructured":"Afarideh M, Aryan Z, Ghajar A, Ganji M, Ghaemi F, Saadat M, et al. Association of non-alcoholic fatty liver disease with microvascular complications of type 2 diabetes. Prim Care Diabetes. 2019;13(6):505\u201314.","journal-title":"Prim Care Diabetes"},{"issue":"5","key":"3096_CR15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.dld.2011.12.005","volume":"44","author":"V de L\u00e9dinghen","year":"2012","unstructured":"de L\u00e9dinghen V, Vergniol J, Gonzalez C, Foucher J, Maury E, Chemineau L, et al. Screening for liver fibrosis by using FibroScan(\u00ae) and fibrotest in patients with diabetes. Dig Liver Dis. 2012;44(5):413\u20138.","journal-title":"Dig Liver Dis"},{"issue":"4","key":"3096_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.14586","volume":"21","author":"L Zhang","year":"2024","unstructured":"Zhang L, Lin Y, Huang X, Zhai Z, Wei R, Mo J, et al. Metabolic dysfunction-associated fatty liver disease in the elderly with diabetic foot ulcers: a longitudinal cohort study. Int Wound J. 2024;21(4):e14586.","journal-title":"Int Wound J"},{"key":"3096_CR17","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2147\/DMSO.S447897","volume":"17","author":"X Huang","year":"2024","unstructured":"Huang X, Li Z, Zhai Z, Wang Q, Wei R, Mo J, et al. Association between metabolic Dysfunction-Associated fatty liver disease and MACCEs in patients with diabetic foot ulcers: an ambispective longitudinal cohort study. Diabetes Metab Syndr Obes. 2024;17:1119\u201330.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"3096_CR18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","volume":"71","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71(1):156\u201362.","journal-title":"Gut"},{"key":"3096_CR19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","volume":"79","author":"A Mantovani","year":"2018","unstructured":"Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis. Metabolism. 2018;79:64\u201376.","journal-title":"Metabolism"},{"issue":"5","key":"3096_CR20","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jhep.2016.06.005","volume":"65","author":"PS Dulai","year":"2016","unstructured":"Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol. 2016;65(5):1006\u201316.","journal-title":"J Hepatol"},{"key":"3096_CR21","volume-title":"Diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO\/IDF consultation","author":"Definition","year":"2006","unstructured":"Definition. and Diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO\/IDF consultation. Geneva, Switzerland: World Health Organization; 2006."},{"key":"3096_CR22","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. Geneva: World Health Organization. Copyright \u00a9 World Health Organization 2011.; 2011."},{"issue":"1","key":"3096_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-021-01763-z","volume":"21","author":"P Nasr","year":"2021","unstructured":"Nasr P, Iredahl F, Dahlstr\u00f6m N, R\u00e5dholm K, Henriksson P, Cedersund G, et al. Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol. BMC Gastroenterol. 2021;21(1):180.","journal-title":"BMC Gastroenterol"},{"key":"3096_CR24","unstructured":"Gastroenterology SSo. Nationell riktlinje - Utredning och handl\u00e4ggning av fettleversjukdom 2020 [Swedish guidelines for NAFLD]. Available from: https:\/\/svenskgastroenterologi.se\/wp-content\/uploads\/2020\/02\/2020-utredning-och-handlaggning-av-fettleversjukdom.pdf. Accessed 2025-10-15."},{"issue":"2","key":"3096_CR25","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/hep.27173","volume":"60","author":"P Bedossa","year":"2014","unstructured":"Bedossa P. Utility and appropriateness of the fatty liver Inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60(2):565\u201375.","journal-title":"Hepatology"},{"issue":"6","key":"3096_CR26","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313\u201321.","journal-title":"Hepatology"},{"issue":"3","key":"3096_CR27","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"EASL-EASD-EASO Clinical","year":"2024","unstructured":"EASL-EASD-EASO Clinical. Practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542.","journal-title":"J Hepatol"},{"issue":"11","key":"3096_CR28","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.15288\/jsa.1982.43.1157","volume":"43","author":"HA Skinner","year":"1982","unstructured":"Skinner HA, Sheu WJ. Reliability of alcohol use indices. The lifetime drinking history and the MAST. J Stud Alcohol. 1982;43(11):1157\u201370.","journal-title":"J Stud Alcohol"},{"issue":"16","key":"3096_CR29","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1001\/archinte.158.16.1789","volume":"158","author":"K Bush","year":"1998","unstructured":"Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory care quality improvement project (ACQUIP). Alcohol use disorders identification test. Arch Intern Med. 1998;158(16):1789\u201395.","journal-title":"Arch Intern Med"},{"issue":"6","key":"3096_CR30","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1002\/hep.26072","volume":"57","author":"D van der Poorten","year":"2013","unstructured":"van der Poorten D, Samer CF, Ramezani-Moghadam M, Coulter S, Kacevska M, Schrijnders D, et al. Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? Hepatology. 2013;57(6):2180\u20138.","journal-title":"Hepatology"},{"issue":"4","key":"3096_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247\u201354.","journal-title":"Ann Intern Med"},{"issue":"6","key":"3096_CR32","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","volume":"67","author":"AS Levey","year":"2005","unstructured":"Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2005;67(6):2089\u2013100.","journal-title":"Kidney Int"},{"issue":"9","key":"3096_CR33","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0161-6420(03)00475-5","volume":"110","author":"CP Wilkinson","year":"2003","unstructured":"Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677\u201382.","journal-title":"Ophthalmology"},{"issue":"5","key":"3096_CR34","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/MEG.0000000000002741","volume":"36","author":"TH Shen","year":"2024","unstructured":"Shen TH, Wu CH, Lee YW, Chang CC. Prevalence, trends, and characteristics of metabolic dysfunction-associated steatotic liver disease among the US population aged 12\u201379 years. Eur J Gastroenterol Hepatol. 2024;36(5):636\u201345.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"3096_CR35","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jdiacomp.2017.11.009","volume":"32","author":"N Nanayakkara","year":"2018","unstructured":"Nanayakkara N, Ranasinha S, Gadowski A, Heritier S, Flack JR, Wischer N, et al. Age, age at diagnosis and diabetes duration are all associated with vascular complications in type 2 diabetes. J Diabetes Complications. 2018;32(3):279\u201390.","journal-title":"J Diabetes Complications"},{"issue":"1","key":"3096_CR36","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s10620-024-08722-0","volume":"70","author":"KC Miller","year":"2025","unstructured":"Miller KC, Geyer B, Alexopoulos AS, Moylan CA, Pagidipati N. Disparities in metabolic dysfunction-associated steatotic liver disease prevalence, diagnosis, treatment, and outcomes: a narrative review. Dig Dis Sci. 2025;70(1):154\u201367.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"3096_CR37","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00592-020-01489-6","volume":"57","author":"SS Singh","year":"2020","unstructured":"Singh SS, van Roeters-Lennep JE, Lemmers RFH, van Herpt TTW, Lieverse AG, Sijbrands EJG. Sex difference in the incidence of microvascular complications in patients with type 2 diabetes mellitus: a prospective cohort study. Acta Diabetol. 2020;57(6):725\u201332.","journal-title":"Acta Diabetol"},{"issue":"4","key":"3096_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2025.102536","volume":"15","author":"FD Mart\u00ednez-S\u00e1nchez","year":"2025","unstructured":"Mart\u00ednez-S\u00e1nchez FD, Corredor-Nassar MJ, Feria-Agudelo SM, Paz-Zarza VM, Martinez-Perez C, Diaz-Jarquin A, et al. Factors associated with advanced liver fibrosis in a population with type 2 diabetes: a multicentric study in Mexico City. J Clin Exp Hepatol. 2025;15(4):102536.","journal-title":"J Clin Exp Hepatol"},{"key":"3096_CR39","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251331315","volume":"18","author":"K Yang","year":"2025","unstructured":"Yang K, Lee J, Han JW, Yang H, Chae SY, Chung BS, et al. A comprehensive analysis of the impact of smoking on adverse clinical outcomes of steatotic liver diseases. Ther Adv Gastroenterol. 2025;18:17562848251331315.","journal-title":"Ther Adv Gastroenterol"},{"issue":"8","key":"3096_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3697","volume":"39","author":"SK Park","year":"2023","unstructured":"Park SK, Kim MH, Jung JY, Oh CM, Ha E, Nam DJ, et al. Changes in smoking status, amount of smoking and their relation to the risk of microvascular complications in men with diabetes mellitus. Diabetes Metab Res Rev. 2023;39(8):e3697.","journal-title":"Diabetes Metab Res Rev"},{"key":"3096_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/joim.20103","author":"W Balkhed","year":"2025","unstructured":"Balkhed W, Bergram M, Iredahl F, Holmberg M, Edin C, Carlh\u00e4ll CJ, et al. Evaluating the prevalence and severity of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus in primary care. J Intern Med. 2025. https:\/\/doi.org\/10.1111\/joim.20103.","journal-title":"J Intern Med"},{"key":"3096_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.719515","volume":"12","author":"S Gao","year":"2021","unstructured":"Gao S, Zhang H, Long C, Xing Z. Association between obesity and microvascular diseases in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2021;12:719515.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3096_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1539283","volume":"12","author":"Z Gao","year":"2025","unstructured":"Gao Z, Deng H, Qin B, Bai L, Li J, Zhang J. Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease. Front Med. 2025;12:1539283.","journal-title":"Front Med"},{"issue":"12","key":"3096_CR44","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1161\/CIRCULATIONAHA.113.002717","volume":"128","author":"J Hata","year":"2013","unstructured":"Hata J, Arima H, Rothwell PM, Woodward M, Zoungas S, Anderson C, et al. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation. 2013;128(12):1325\u201334.","journal-title":"Circulation"},{"issue":"1","key":"3096_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-025-03659-8","volume":"25","author":"XM Ma","year":"2025","unstructured":"Ma XM, Guo YM, Jiang SY, Li KX, Zheng YF, Guo XG, et al. Potential predictive role of non-HDL to HDL cholesterol ratio (NHHR) in MASLD: focus on obese and type 2 diabetic populations. BMC Gastroenterol. 2025;25(1):79.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"3096_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1507\/endocrj.EJ24-0189","volume":"72","author":"M Han","year":"2025","unstructured":"Han M, Shen Y, Guo X, Hong C, Ji X, Guo H, et al. Association between non-high-density lipoprotein cholesterol and type 2 diabetes: a systematic review and meta-analysis of cohort studies. Endocr J. 2025;72(1):43\u201351.","journal-title":"Endocr J"},{"key":"3096_CR47","doi-asserted-by":"crossref","unstructured":"Baek SU, Yoon JH, High-Sensitivity C-R. Protein levels in metabolic dysfunction-Associated steatotic liver disease (MASLD), metabolic Alcohol-Associated liver disease (MetALD), and alcoholic liver disease (ALD) with metabolic dysfunction. Biomolecules. 2024;14(11):1486.","DOI":"10.3390\/biom14111468"},{"key":"3096_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.885516","volume":"13","author":"M Tang","year":"2022","unstructured":"Tang M, Cao H, Wei XH, Zhen Q, Liu F, Wang YF, et al. Association between high-sensitivity C-reactive protein and diabetic kidney disease in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2022;13:885516.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3096_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.04.019","author":"J Vaz","year":"2025","unstructured":"Vaz J, Nasr P, Helander A, Shang Y, Wester A, Strandberg R, et al. Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.04.019.","journal-title":"J Hepatol"},{"issue":"1","key":"3096_CR50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/1753-0407.12822","volume":"11","author":"R Elgendy","year":"2019","unstructured":"Elgendy R, Desch\u00eanes SS, Burns RJ, Levy M, Schmitz N. Alcohol consumption, depressive symptoms, and the incidence of diabetes-related complications. J Diabetes. 2019;11(1):14\u201322.","journal-title":"J Diabetes"},{"key":"3096_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/metabo14040186","author":"F Perazza","year":"2024","unstructured":"Perazza F, Leoni L, Colosimo S, Musio A, Bocedi G, D\u2019Avino M, et al. Metformin and the liver: unlocking the full therapeutic potential. Metabolites. 2024. https:\/\/doi.org\/10.3390\/metabo14040186.","journal-title":"Metabolites"},{"issue":"1","key":"3096_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-025-01577-w","volume":"24","author":"M Bahardoust","year":"2025","unstructured":"Bahardoust M, Mehrabi Y, Hadaegh F, Azizi F, Khalili D, Delpisheh A. The association between duration of Metformin and sulfonylurea treatment and microvascular complications in patients with incident type 2 diabetes: a pooled cohort analysis. J Diabetes Metab Disord. 2025;24(1):94.","journal-title":"J Diabetes Metab Disord"},{"issue":"1","key":"3096_CR53","first-page":"47","volume":"13","author":"MW Wang","year":"2025","unstructured":"Wang MW, Lu LG. Current status of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: a clinical perspective. J Clin Transl Hepatol. 2025;13(1):47\u201361.","journal-title":"J Clin Transl Hepatol"},{"issue":"10","key":"3096_CR54","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00592-017-1031-9","volume":"54","author":"I Dicembrini","year":"2017","unstructured":"Dicembrini I, Nreu B, Scatena A, Andreozzi F, Sesti G, Mannucci E, et al. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2017;54(10):933\u201341.","journal-title":"Acta Diabetol"},{"issue":"20","key":"3096_CR55","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2016.08.42","volume":"4","author":"AM Jingi","year":"2016","unstructured":"Jingi AM, Noubiap JJ, Essouma M, Bigna JJ, Nansseu JR, Ellong A, et al. Association of insulin treatment versus oral hypoglycaemic agents with diabetic retinopathy and its severity in type 2 diabetes patients in Cameroon, sub-Saharan Africa. Ann Transl Med. 2016;4(20):395.","journal-title":"Ann Transl Med"},{"issue":"6","key":"3096_CR56","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/jdi.12518","volume":"7","author":"LH Yan","year":"2016","unstructured":"Yan LH, Mu B, Guan Y, Liu X, Zhao N, Pan D, et al. Assessment of the relationship between non-alcoholic fatty liver disease and diabetic complications. J Diabetes Investig. 2016;7(6):889\u201394.","journal-title":"J Diabetes Investig"},{"issue":"6","key":"3096_CR57","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1159\/000528080","volume":"147","author":"T Adrian","year":"2023","unstructured":"Adrian T, Hornum M, Knop FK, Almdal T, Rossing P. Nonalcoholic fatty liver disease in patients with type 2 diabetes and chronic kidney disease. Nephron. 2023;147(6):317\u201328.","journal-title":"Nephron"},{"issue":"4","key":"3096_CR58","doi-asserted-by":"publisher","first-page":"638","DOI":"10.4254\/wjh.v7.i4.638","volume":"7","author":"M Papagianni","year":"2015","unstructured":"Papagianni M, Sofogianni A, Tziomalos K. Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World J Hepatol. 2015;7(4):638\u201348.","journal-title":"World J Hepatol"},{"issue":"8","key":"3096_CR59","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.jdiacomp.2015.06.015","volume":"29","author":"KH Williams","year":"2015","unstructured":"Williams KH, Burns K, Constantino M, Shackel NA, Prakoso E, Wong J, et al. An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes. J Diabetes Complications. 2015;29(8):1240\u20137.","journal-title":"J Diabetes Complications"},{"issue":"1","key":"3096_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03870-z","volume":"11","author":"K Kim","year":"2021","unstructured":"Kim K, Oh TJ, Cho HC, Lee YK, Ahn CH, Koo BK, et al. Liver fibrosis indices are related to diabetic peripheral neuropathy in individuals with type 2 diabetes. Sci Rep. 2021;11(1):24372.","journal-title":"Sci Rep"},{"issue":"5","key":"3096_CR61","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/07853890.2018.1492147","volume":"50","author":"AJ K\u00e4r\u00e4j\u00e4m\u00e4ki","year":"2018","unstructured":"K\u00e4r\u00e4j\u00e4m\u00e4ki AJ, Hukkanen J, Ukkola O. The association of non-alcoholic fatty liver disease and atrial fibrillation: a review. Ann Med. 2018;50(5):371\u201380.","journal-title":"Ann Med"},{"issue":"3","key":"3096_CR62","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","volume":"78","author":"V Ajmera","year":"2023","unstructured":"Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol. 2023;78(3):471\u20138.","journal-title":"J Hepatol"},{"issue":"1","key":"3096_CR63","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/liv.15730","volume":"44","author":"R Forlano","year":"2024","unstructured":"Forlano R, Stanic T, Jayawardana S, Mullish BH, Yee M, Mossialos E, et al. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies. Liver Int. 2024;44(1):61\u201371.","journal-title":"Liver Int"},{"issue":"5","key":"3096_CR64","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/j.1478-3231.2011.02482.x","volume":"31","author":"NC Leite","year":"2011","unstructured":"Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, et al. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int. 2011;31(5):700\u20136.","journal-title":"Liver Int"},{"issue":"7","key":"3096_CR65","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.2337\/dc14-1239","volume":"38","author":"J Bazick","year":"2015","unstructured":"Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, et al. Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD. Diabetes Care. 2015;38(7):1347\u201355.","journal-title":"Diabetes Care"},{"key":"3096_CR66","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.bbacli.2014.09.001","volume":"3","author":"GB Goh","year":"2015","unstructured":"Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C, et al. Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. BBA Clin. 2015;3:141\u20135.","journal-title":"BBA Clin"},{"key":"3096_CR67","unstructured":"National Board of Health and Welfare. Nationella riktlinjer f\u00f6r diabetesv\u00e5rd [Swedish guidelines for diabetes 2018]. Available from: https:\/\/www.socialstyrelsen.se\/publikationer\/nationella-riktlinjer-for-diabetesvard--stod-for-styrning-och-ledning-2018-10-25\/.\u00a0Accessed 2025-10-15."},{"issue":"1","key":"3096_CR68","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2024.02.022","volume":"23","author":"SA Harrison","year":"2025","unstructured":"Harrison SA, Frias JP, Lucas KJ, Reiss G, Neff G, Bollepalli S, et al. Safety and efficacy of efruxifermin in combination with a GLP-1 receptor agonist in patients with NASH\/MASH and type 2 diabetes in a randomized phase 2 study. Clin Gastroenterol Hepatol. 2025;23(1):103\u201313.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["BMC Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-025-03096-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12875-025-03096-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-025-03096-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T08:02:25Z","timestamp":1762848145000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcfampract.biomedcentral.com\/articles\/10.1186\/s12875-025-03096-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3096"],"URL":"https:\/\/doi.org\/10.1186\/s12875-025-03096-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6925290\/v1","asserted-by":"object"}]},"ISSN":["2731-4553"],"issn-type":[{"value":"2731-4553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The EPSOMIP study received approval from the Regional Ethical Board of \u00d6sterg\u00f6tland (2018\/176\u2009\u2212\u200931 and 2018\/494\u2009\u2212\u200932) and is registered as a clinical trial under the identifier NCT03864510 at ClinicalTrials.gov (registration date: 2019-02-12). This study was conducted in accordance with the Declaration of Helsinki. At the time of inclusion, participants received both oral and written information about the study. Those who agreed to participate provided written informed consent. Informed consent was obtained from all participants in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FI has received speaker fees and served on advisory boards for Novo Nordisk, Sanofi, and Boehringer Ingelheim. ME is the recipient of lecture fees from Novo Nordisk. PN has served on advisory boards f\u00f6r Boehringer Ingelheim.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"354"}}